Health Insight
Life Sciences
-
Why Vaccines Should be Part of Your Respiratory Disease Prevention Strategy
Aging, a weakening immune system, plus increased exposures can leave older individuals vulnerable to many diseases. That’s why immunization is so important. Immunization is key to disease prevention, especially for older adults. “With aging, people often have other medical conditions and comorbidities. That, along with a weakened immune system, can leave them vulnerable to serious infection...
-
Minister Champagne Highlights Canada’s Commitment to Life Sciences Sector Growth
Government prioritizes health and innovation with investments in biomanufacturing and life sciences strategy.
-
Boosting Ontario’s Life Sciences: Insights from an Industry Leader
Life Science Ontario (LSO) highlights the provinces commitment to advancing the sector. Learn more at lifesciencesontario.ca
-
Durhane Wong-Rieger Discusses Canadian Rare Disease Drug Strategy
The $1.5 billion initiative aims to propel Ontario’s rare disease care and innovation. Learn more at raredisorders.ca
-
The Value of Real-World Evidence in Canadian Drug Commercialization
Increasingly, Canadian payers and regulators find value in outcomes-based evidence beyond randomized controlled trials in regulatory and reimbursement decision-making through the utilization of real-world evidence (RWE). For example, last year, CDA[1] (previously CADTH) in association with Health Canada and INESSS, has produced guidance for regulatory and health technology assessment agencies to advance the integration of...
-
Why We Must Improve Patients’ Access to Innovative Medicines in Canada
Canada’s policy environment must improve to get innovative new medicines to the patients who need them. Canada’s complex regulatory and reimbursement pathway means that patients must wait two years (732 days), on average, for access to approved new medicines through public drug plans — which puts us far behind peer countries including the U.S. and...
-
s Sponsored
Patients Deserve Faster Access to Innovative New Medicines
Long wait times for new medicines in Canada, averaging two years, hinder patient access and limit life sciences investments. Nolan Caskanette was only six weeks old when his mother, Kerri Beirnes, noticed he couldn’t lift his head during tummy time — something his sister Fiona had done easily when she was the same age. By...
-
s Sponsored
Toronto Neo Biotech Discovering Patient Solutions with AI
With the vast amounts of biochemical and healthcare data available, Cyclica is focused on designing drugs for patients — not just for proteins.
-
s Sponsored
Quebec Drug Discovery Model Draws Global Attention
IRICoR specializes in drug discovery. Its network and resources are set to benefit a growing pool of Canadian and international drug discovery innovators.